SEC-sourced researchBeta
XLO
Xilio Therapeutics, Inc.
Company comparison ↗
Data passport
- CIK
- 0001840233
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Oct 2, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2024 | 6,344,000.0000 | Mar 23, 2026 |
| December 2025 | 43,766,000.0000 | Mar 23, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 43,766,000.0000 | -35,036,000.0000 | -4,992,000.0000 | 154,685,000.0000 | 119,412,000.0000 | Mar 23, 2026 |
| December 2024 | 6,344,000.0000 | -58,241,000.0000 | -18,378,000.0000 | 71,075,000.0000 | 53,477,000.0000 | Mar 23, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $43.77M | December 2025 | Mar 23, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $6.34M | December 2024 | Mar 23, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$35.04M | December 2025 | Mar 23, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$4.99M | December 2025 | Mar 23, 2026 | 10-K |
| Total assetsAssets | $154.69M | December 2025 | Mar 23, 2026 | 10-K |
| Total liabilitiesLiabilities | $119.41M | December 2025 | Mar 23, 2026 | 10-K |